{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-007828","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.356767+00:00","generated_at":"2026-05-15T13:47:22.036285+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clene reports FY2025 net loss $26.2M; cash $5.2M; FDA type C meeting planned","bullets":["Net loss of $26.2M ($2.65 per share) vs $39.4M ($5.67) in 2024.","R&D expenses $14.0M, down from $20.1M; G&A $9.2M, down from $13.3M.","Cash and equivalents $5.2M at Dec 31, 2025; expected runway to Q3 2026 after Jan 2026 offering.","Oversubscribed $28M registered direct offering; initial tranche $6M priced above market.","Type C FDA meeting before end of Mar 2026; NDA filing for CNM-Au8 in ALS by June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-007828","json":"https://secwatch.observer/filing/0001437749-26-007828.json","markdown":"https://secwatch.observer/filing/0001437749-26-007828.md","text":"https://secwatch.observer/filing/0001437749-26-007828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926007828/0001437749-26-007828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926007828/clnn20251022_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:47:22.036285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}